World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 1: Acute treatment of schizophrenia
Authors:
- Peter FalkaiPFPeter Falkai
- Thomas WobrockTWThomas Wobrock
- Birte GlenthojBGBirte Glenthoj
- Wfsbp Task Force On Treatment Guidelines For SchizophreniaWSWfsbp Task Force On Treatment Guidelines For Schizophrenia
Open Access
- 1 January 2005
- journal article
- review article
- Published by Taylor & Francis in The World Journal of Biological Psychiatry
- Vol. 6 (3) , 132-191
Abstract
These guidelines for the biological treatment of schizophrenia were developed by an international Task Force of the World Federation of Societies of Biological Psychiatry (WFSBP). The goal during the development of these guidelines was to review systematically all available evidence pertaining to the treatment of schizophrenia, and to reach a consensus on a series of practice recommendations that are clinically and scientifically meaningful based on the available evidence. These guidelines are intended for use by all physicians seeing and treating people with schizophrenia. The data used for developing these guidelines have been extracted primarily from various national treatment guidelines and panels for schizophrenia, as well as from meta-analyses, reviews and randomised clinical trials on the efficacy of pharmacological and other biological treatment interventions identified by a search of the MEDLINE database and Cochrane Library. The identified literature was evaluated with respect to the strength of evidence for its efficacy and then categorised into four levels of evidence (A–D). This first part of the guidelines covers disease definition, classification, epidemiology and course of schizophrenia, as well as the management of the acute phase treatment. These guidelines are primarily concerned with the biological treatment (including antipsychotic medication, other pharmacological treatment options, electroconvulsive therapy, adjunctive and novel therapeutic strategies) of adults suffering from schizophrenia.Keywords
This publication has 489 references indexed in Scilit:
- The effectiveness of olanzapine in treatment-refractory schizophrenia when patients are nonresponsive to or unable to tolerate clozapineClinical Therapeutics, 2000
- Comparative efficacy of olanzapine and haloperidol for patients with treatment-resistant schizophrenia∗∗See accompanying Editorial, in this issue.Biological Psychiatry, 1999
- Synergism of lorazepam and electroconvulsive therapy in the treatment of catatoniaBiological Psychiatry, 1997
- Multiple fixed doses of “Seroquel” (quetiapine) in patients with acute exacerbation of schizophrenia: A comparison with haloperidol and placeboBiological Psychiatry, 1997
- Olanzapine versus Placebo and HaloperidolNeuropsychopharmacology, 1996
- ICI 204,636, a novel, atypical antipsychotic: early indication of safety and efficacy in patients with chronic and subchronic schizophreniaClinical Therapeutics, 1995
- A pilot, open study on the treatment of refractory schizophrenia with risperidone and clozapineHuman Psychopharmacology: Clinical and Experimental, 1995
- Effects of alcohol on serum fluphenazine levels in stable chronic schizophrenicsHuman Psychopharmacology: Clinical and Experimental, 1991
- Combined electroconvulsive and neuroleptic therapy in schizophrenia refractory to neurolepticsSchizophrenia Research, 1990
- PROPRANOLOL AS AN ADJUNCT TO THE TREATMENT OF SCHIZOPHRENIAThe Lancet, 1977